Cadrenal Therapeutics, Inc.

As of June 20, 2025, Cadrenal Therapeutics, Inc. is in a bearish trend, indicated by a bearish MACD, negative Bollinger Bands, and weak RSI and KST readings across multiple time frames.

Cadrenal Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $4 million and a market cap of $25.82 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -174.24%.

As of Jun 18, Cadrenal Therapeutics, Inc. has a market capitalization of 25.82 million, with net sales of 0.00 million and a net profit of -12.84 million over the last four quarters. The company reported shareholder's funds of 7.44 million and total assets of 10.12 million as of Dec 24.